176 related articles for article (PubMed ID: 34830748)
1. Conversion of Osteoclasts into Bone-Protective, Tumor-Suppressing Cells.
Li KX; Sun X; Li BY; Yokota H
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830748
[TBL] [Abstract][Full Text] [Related]
2. Suppression of breast cancer-associated bone loss with osteoblast proteomes via Hsp90ab1/moesin-mediated inhibition of TGFβ/FN1/CD44 signaling.
Sun X; Li K; Hase M; Zha R; Feng Y; Li BY; Yokota H
Theranostics; 2022; 12(2):929-943. PubMed ID: 34976221
[No Abstract] [Full Text] [Related]
3. Generation of the tumor-suppressive secretome from tumor cells.
Liu S; Sun X; Li K; Zha R; Feng Y; Sano T; Dong C; Liu Y; Aryal UK; Sudo A; Li BY; Yokota H
Theranostics; 2021; 11(17):8517-8534. PubMed ID: 34373756
[No Abstract] [Full Text] [Related]
4. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M
Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935
[TBL] [Abstract][Full Text] [Related]
5. Counterintuitive production of tumor-suppressive secretomes from Oct4- and c-Myc-overexpressing tumor cells and MSCs.
Li K; Sun X; Zha R; Liu S; Feng Y; Sano T; Aryal UK; Sudo A; Li BY; Yokota H
Theranostics; 2022; 12(7):3084-3103. PubMed ID: 35547745
[No Abstract] [Full Text] [Related]
6. Proteomes from AMPK-inhibited peripheral blood mononuclear cells suppress the progression of breast cancer and bone metastasis.
Li K; Sun X; Minami K; Tamari K; Ogawa K; Li H; Ma H; Zhou M; Na S; Li BY; Yokota H
Theranostics; 2023; 13(4):1247-1263. PubMed ID: 36923539
[No Abstract] [Full Text] [Related]
7. PI3K-activated MSC proteomes inhibit mammary tumors via Hsp90ab1 and Myh9.
Sun X; Li K; Aryal UK; Li BY; Yokota H
Mol Ther Oncolytics; 2022 Sep; 26():360-371. PubMed ID: 36090473
[TBL] [Abstract][Full Text] [Related]
8. Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer-induced bone cell activity, bone remodeling, and osteolysis.
Logan JG; Sophocleous A; Marino S; Muir M; Brunton VG; Idris AI
J Bone Miner Res; 2013 May; 28(5):1229-42. PubMed ID: 23239200
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cells development into osteoclast-type APCs by 4T1 breast tumor T cells milieu boost bone consumption.
Monteiro AC; Bonomo A
Bone; 2021 Feb; 143():115755. PubMed ID: 33217627
[TBL] [Abstract][Full Text] [Related]
10. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand.
Itoh K; Udagawa N; Katagiri T; Iemura S; Ueno N; Yasuda H; Higashio K; Quinn JM; Gillespie MT; Martin TJ; Suda T; Takahashi N
Endocrinology; 2001 Aug; 142(8):3656-62. PubMed ID: 11459815
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor beta derived from bone matrix promotes cell proliferation of prostate cancer and osteoclast activation-associated osteolysis in the bone microenvironment.
Sato S; Futakuchi M; Ogawa K; Asamoto M; Nakao K; Asai K; Shirai T
Cancer Sci; 2008 Feb; 99(2):316-23. PubMed ID: 18271931
[TBL] [Abstract][Full Text] [Related]
12. Tetrahydrofurofuran-type lignans inhibit breast cancer-mediated bone destruction by blocking the vicious cycle between cancer cells, osteoblasts and osteoclasts.
Jun AY; Kim HJ; Park KK; Son KH; Lee DH; Woo MH; Chung WY
Invest New Drugs; 2014 Feb; 32(1):1-13. PubMed ID: 23673814
[TBL] [Abstract][Full Text] [Related]
13. Quetiapine inhibits osteoclastogenesis and prevents human breast cancer-induced bone loss through suppression of the RANKL-mediated MAPK and NF-κB signaling pathways.
Wang H; Shen W; Hu X; Zhang Y; Zhuo Y; Li T; Mei F; Li X; Xiao L; Chu T
Breast Cancer Res Treat; 2015 Feb; 149(3):705-14. PubMed ID: 25667102
[TBL] [Abstract][Full Text] [Related]
14. Theaflavin-3,3'-digallate represses osteoclastogenesis and prevents wear debris-induced osteolysis via suppression of ERK pathway.
Hu X; Ping Z; Gan M; Tao Y; Wang L; Shi J; Wu X; Zhang W; Yang H; Xu Y; Wang Z; Geng D
Acta Biomater; 2017 Jan; 48():479-488. PubMed ID: 27838465
[TBL] [Abstract][Full Text] [Related]
15. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
[TBL] [Abstract][Full Text] [Related]
16. Human breast cancer induces osteoclast activation and increases the number of osteoclasts at sites of tumor osteolysis.
Clohisy DR; Palkert D; Ramnaraine ML; Pekurovsky I; Oursler MJ
J Orthop Res; 1996 May; 14(3):396-402. PubMed ID: 8676252
[TBL] [Abstract][Full Text] [Related]
17. IL-11 produced by breast cancer cells augments osteoclastogenesis by sustaining the pool of osteoclast progenitor cells.
McCoy EM; Hong H; Pruitt HC; Feng X
BMC Cancer; 2013 Jan; 13():16. PubMed ID: 23311882
[TBL] [Abstract][Full Text] [Related]
18. Melatonin attenuates titanium particle-induced osteolysis via activation of Wnt/β-catenin signaling pathway.
Ping Z; Hu X; Wang L; Shi J; Tao Y; Wu X; Hou Z; Guo X; Zhang W; Yang H; Xu Y; Wang Z; Geng D
Acta Biomater; 2017 Mar; 51():513-525. PubMed ID: 28088671
[TBL] [Abstract][Full Text] [Related]
19. Asperolide A prevents bone metastatic breast cancer via the PI3K/AKT/mTOR/c-Fos/NFATc1 signaling pathway.
Jiang W; Rixiati Y; Huang H; Shi Y; Huang C; Jiao B
Cancer Med; 2020 Nov; 9(21):8173-8185. PubMed ID: 32976685
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory Effect of (2
Kim EN; Kim GR; Yu JS; Kim KH; Jeong GS
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33379346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
